1505 Adams Dr., Ste. D
15 articles with BioPharmX
BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering.
BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference
BioPharmX Corporation today announced presentations at multiple upcoming investor conferences.
Dr. R. Todd Plott, developer of SOLODYN™, ZIANA™, and NORITATE™, becomes company's third independent director
BioPharmX Corporation received a notice on December 17, 2018 from the NYSE American LLC (the "NYSE American") that the Company is not in compliance with the stockholders' equity requirements set forth in Section 1003(a)(i) and Section 1003(a)(ii) of the NYSE American Company Guide.
BioPharmX Corporation announced that on November 1, 2018, NYSE Regulation accepted the Company's plan to regain compliance with the NYSE American LLC ("NYSE American") continued listing standards set forth in Sections 1003(a)(iii) of the NYSE American Company Guide.
Trial will evaluate 1% concentration of minocycline carried by company's patented HyantX™ delivery system
BioPharmX (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, received a notice on September 24, 2018 from the NYSE American LLC (the "NYSE American") that the Company is not in compliance with the stockholders' equity requirements set forth in Sections 1003(a)(i)-(iii) of the NYSE American Company Guide.
BioPharmX Corporation held its 2018 Annual Meeting of Shareholders, and announced that each of BioPharmX's director nominees have been re-elected to the board of directors: Anja Krammer, Michael Hubbard and Stephen Morlock.
New patent protects improvements in oral drug delivery
Open-label feasibility study results identify BPX-04 topical minocycline gel, 1% as optimal dose for phase 2 trial
BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that the U.S. Food and Drug Administration has waived its requirement for a dermal carcinogenicity study for BPX-01, eliminating several years of non-clinical research normally required for FDA review.
Not satisfied with the pharmaceutical industry's pace of change, BioPharmX picks team of 'best and brightest' experts to identify evolving needs of patients and physicians
BioPharmX Corporation reports financial results for the quarter ended April 30, 2018.
BioPharmX Studies Show Hydrophilic Topical Minocycline Gels May Be the Preferred Treatment Option for Acne, Rosacea Patients
For the first time, BioPharmX will share its research at the Congress of Clinical Dermatology
BioPharmX Corporation reports financial results for the quarter and year ended January 31, 2018.